Genomics England

Genomics England was established in 2013 by the UK Department of Health & Social Care to deliver the ambitious national-scale “100,000 Genomes Project,” which successfully sequenced over 100,000 whole genomes from NHS patients with rare diseases or cancer by late 2018. The company now operates at scale as an integrated part of the UK’s healthcare ecosystem—enabling routine genomic testing within the NHS and providing one of the world’s richest genomic datasets for approved researchers worldwide. Its work has led directly to improved diagnosis rates in rare disease (~20–25% actionable findings) and identified new mutational profiles in cancer (~50% cases with potential therapy/clinical trial implications). It continues to drive innovation through partnerships with academic institutions, industry leaders like Illumina, Wellcome Trust investments in infrastructure near Cambridge/Sanger Institute/EBI campus, and ongoing collaborations across government-funded health initiatives.